Identifies new business opportunities arising out of the Laboratory’s research and development strategies.
About BJ Bormann
BJ Bormann joined The Jackson Laboratory, a nonprofit biomedical research institution, in 2017 with nearly 30 years of experience in both pharmaceutical and academic science, as well as leadership in biotech and pharmaceutical business development and licensing. BJ recently served as Senior Vice President responsible for Worldwide Alliances, Licensing and Business Development at Boehringer Ingelheim Pharmaceuticals, Inc., along with a number of positions at Pfizer, Inc. (NYSE: PFE), including Vice President of Pfizer Global Research and Development and the Global Head of Strategic Alliances. BJ has also served in the biotechnology area as CEO of Supportive Therapeutics, LLC, the CEO of Pivot Pharmaceuticals (OTC: PVOTF) and CEO of Harbour Antibodies based in the Netherlands. She currently serves on the board of directors of Bioline RX (BLRX: NASDAQ) and Xeris Pharmaceuticals (XERS:NASDAQ). BJ previously served on the Boards for CURE, CBIA and BIO. BJ received her Ph.D. in biomedical science from the University of Connecticut Health Center and her B.Sc. from Fairfield University in biology. She completed her postdoctoral training at the Yale School of Medicine in the department of pathology.
BJ Bormann has joined nonprofit biomedical research institution, The Jackson Laboratory, as vice president, translational science and network alliances.
These cookies are required for basic site operations.
Allow Essential cookies
Analytics cookies are used to analyze web traffic to improve the user experience.
Allow Analytics cookies